Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1912 2
1913 2
1915 1
1917 1
1918 3
1920 1
1921 1
1924 3
1925 3
1928 4
1929 2
1930 2
1932 4
1934 1
1935 1
1938 1
1940 2
1941 1
1942 2
1944 1
1945 2
1946 5
1947 1
1948 3
1949 2
1955 2
1961 1
1962 2
1963 2
1964 1
1965 1
1966 1
1968 1
1970 4
1971 1
1972 2
1973 4
1974 5
1975 3
1976 6
1977 4
1978 6
1979 3
1980 4
1981 4
1982 3
1983 1
1984 2
1986 5
1987 2
1988 2
1989 2
1990 6
1991 2
1992 2
1993 3
1994 5
1995 7
1996 1
1997 1
1998 2
1999 1
2000 1
2001 1
2002 6
2003 2
2004 2
2005 10
2006 10
2007 6
2008 20
2009 11
2010 13
2011 28
2012 27
2013 28
2014 30
2015 32
2016 43
2017 39
2018 39
2019 30
2020 29
2021 38
2022 29
2023 34
2024 32
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

649 results

Results by year

Filters applied: . Clear all
Page 1
Amanda Cohn Comments.
Cohn A. Cohn A. Am J Public Health. 2019 Dec;109(12):1717. doi: 10.2105/AJPH.2019.305387. Am J Public Health. 2019. PMID: 31693418 Free PMC article. No abstract available.
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Among authors: cohn al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M. Makker V, et al. Among authors: cohn al. Lancet Oncol. 2019 May;20(5):711-718. doi: 10.1016/S1470-2045(19)30020-8. Epub 2019 Mar 25. Lancet Oncol. 2019. PMID: 30922731 Free PMC article. Clinical Trial.
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lee CH, et al. Among authors: cohn al. Lancet Oncol. 2021 Jul;22(7):946-958. doi: 10.1016/S1470-2045(21)00241-2. Epub 2021 Jun 15. Lancet Oncol. 2021. PMID: 34143969 Free PMC article. Clinical Trial.
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer.
Makker V, Taylor MH, Aghajanian C, Oaknin A, Mier J, Cohn AL, Romeo M, Bratos R, Brose MS, DiSimone C, Messing M, Stepan DE, Dutcus CE, Wu J, Schmidt EV, Orlowski R, Sachdev P, Shumaker R, Casado Herraez A. Makker V, et al. Among authors: cohn al. J Clin Oncol. 2020 Sep 10;38(26):2981-2992. doi: 10.1200/JCO.19.02627. Epub 2020 Mar 13. J Clin Oncol. 2020. PMID: 32167863 Free PMC article. Clinical Trial.
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Lenz HJ, et al. Among authors: cohn al. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409. J Immunother Cancer. 2024. PMID: 38485190 Free PMC article. Clinical Trial.
Reply.
Gillies MC, Nguyen CL, Nguyen V, Daien V, Cohn A, Banerjee G, Arnold J; Fight Retinal Blindness! Study Group. Gillies MC, et al. Among authors: cohn a. Ophthalmology. 2020 Apr;127(4):e21-e22. doi: 10.1016/j.ophtha.2019.10.031. Ophthalmology. 2020. PMID: 32200844 No abstract available.
649 results